GET DAILY SIGNALSAchieve Life Sciences (ACHV) Q3 2026 Earnings: What Investors Should Watch
Key Takeaways
- Achieve Life Sciences is expected to report its third quarter 2026 results in early November, with Wall Street consensus calling for a loss of roughly $0.20 per share.
- As a pre-revenue, late-stage biopharmaceutical company, the focus will be on operating expenses, cash runway, and regulatory progress rather than top-line sales.
- Investors will be watching closely for any update on the planned resubmission of the New Drug Application (NDA) for cytisinicline in the fourth quarter of 2026.
- The company's prior quarter came in well below expectations, reporting a loss of $0.80 per share versus a $0.16 consensus, driven largely by non-cash items tied to its April financing.
- A strengthened balance sheet, supported by a private placement of up to $354 million ($180 million upfront), has reduced near-term funding concerns ahead of a potential 2027 launch.
Why This Quarter Matters
Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on cytisinicline, a plant-based candidate being developed as a treatment for nicotine dependence, including smoking and vaping cessation. With no commercial products on the market, quarterly earnings serve less as a profit statement and more as a report card on cash burn and execution. The company has completed two Phase 3 smoking cessation trials and a Phase 2 vaping study, and the U.S. Food and Drug Administration (FDA) has granted cytisinicline Breakthrough Therapy designation for vaping cessation. After receiving a Complete Response Letter (CRL) earlier in 2026 related to a third-party manufacturer, Achieve has shifted production to U.S.-based Adare Pharma Solutions and is targeting an NDA resubmission in late 2026. This report should clarify whether that timeline remains on track. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect ACHV to report a net loss of approximately $0.20 per share for the third quarter of 2026, with individual estimates ranging from about -$0.19 to -$0.22. Because the company remains pre-revenue, consensus revenue expectations are effectively zero, and investors will instead scrutinize research and development (R&D) and general and administrative (G&A) spending. In the second quarter of 2026, Achieve posted a loss of $0.80 per share, far wider than the $0.16 consensus, a miss driven substantially by non-cash accounting charges associated with warrants issued in its April private placement rather than a fundamental deterioration in operations. Management has not issued formal quarterly earnings guidance, so the key information will come from commentary on the NDA resubmission timing, manufacturing readiness with Adare, and the status of the ORCA-V2 vaping study.
Market Reaction and Investor Sentiment
Sentiment heading into this earnings report is defined by regulatory milestones rather than quarterly financials. Achieve Life Sciences shares have been volatile around prior announcements, with the stock historically showing outsized moves tied to clinical and regulatory news. The second quarter 2026 report, which featured a wide per-share loss caused by non-cash items, was followed by relatively muted trading as investors looked past accounting noise toward the cytisinicline approval pathway. Heading into the third quarter update, investors will be listening for confirmation that the NDA resubmission remains on schedule for the fourth quarter of 2026 and that the transition to Adare Pharma Solutions has not introduced delays. Any shift in the expected first-half 2027 approval timeline would be a key risk factor for sentiment. From what I see, this is important because regulatory updates tend to drive the larger moves here.
Forward Outlook and Key Factors to Monitor
The most important forward-looking variable for Achieve Life Sciences is the timing and content of its NDA resubmission for cytisinicline. Management has reiterated a plan to resubmit in the fourth quarter of 2026, with a potential commercial launch in the first half of 2027, if approved. Investors should monitor whether the company confirms this timeline or signals any adjustment tied to manufacturing validation or regulatory feedback.
A second factor is the company's cash position. The April 2026 private placement provided $180 million upfront, with up to $174 million in additional milestone-linked warrants exercisable within a defined window following FDA approval. This capital is intended to fund the resubmission and initial commercial buildout, but spending discipline across R&D and the expanding commercial team will remain a focus given the company's pre-revenue status.
Finally, watch for progress on the broader clinical program, including the planned ORCA-V2 Phase 3 study in vaping cessation and any additional efficacy data presentations. As a clinical-stage company, regulatory and clinical catalysts — not quarterly earnings — are likely to remain the primary drivers of the stock, and investors should weigh these milestones against the inherent risks of drug development. I’m watching this closely as the NDA timeline unfolds.
Using Tickeron’s AI Tools in My Research
In my analysis of development-stage names like ACHV, I often rely on Tickeron’s AI Screener to quickly filter for technical patterns, volatility signals, and sector momentum. It helps me spot setups around binary events without spending hours on manual charts, and I find the customizable filters particularly useful when comparing regulatory catalysts across the biotech space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACHV in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
ACHV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 43 cases where ACHV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACHV's RSI Oscillator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on ACHV as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ACHV just turned positive on October 28, 2026. Looking at past instances where ACHV's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Following a +5.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHV advanced for three days, in 212 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 54 cases where ACHV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
ACHV moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACHV crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ACHV entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-48.941) is normal, around the industry mean (2.904). P/E Ratio (-4.205) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ACHV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of specialty pharmaceuticals
Industry Biotechnology
Advertisement